InsiderDirector
Noubar Afeyan Insider Trading Activity
Every SEC Form 4 transaction reported by Noubar Afeyan, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Is Noubar Afeyan buying or selling?
Noubar Afeyan reported 3 open-market buys ($170.0M) and 86 sells ($1.6B) across 89 Form 4 filings at 3 companies — a net selling position of $1.5B.
Source: SEC EDGAR Form 4
Key Statistics (as of May 22, 2026)
Total Form 4 filings
89
SEC EDGAR
Companies
3
Buys (3)
$170.0M
Sells (86)
$1.6B
Insider sentiment
Net sellingNet insider flow of $1.5B in net selling, filed between Jun 20, 2019 – May 22, 2026.
Companies Noubar Afeyan files for
Recent Noubar Afeyan transactions
| Date | Ticker | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| May 22, 2026 | MRNA | Director | Sale | 9.3K | $433.9K |
| Mar 2, 2026 | GENB | Director, 10% Owner | Purchase | 4.7M | $75.0M |
| Mar 2, 2026 | GENB | Director, 10% Owner | Purchase | 4.7M | $75.0M |
| Dec 15, 2025 | MRNA | Director | Sale | 23.9K | $703.3K |
| Aug 2, 2024 | MRNA | Director | Sale | 15.0K | $1.8M |
| Jul 26, 2024 | MRNA | Director | Sale | 15.0K | $1.8M |
| Jul 19, 2024 | MRNA | Director | Sale | 15.0K | $1.8M |
| Jul 12, 2024 | MRNA | Director | Sale | 15.0K | $1.8M |
| Jun 28, 2024 | MRNA | Director | Sale | 15.0K | $1.9M |
| Jun 21, 2024 | MRNA | Director | Sale | 15.0K | $2.0M |
| Jun 14, 2024 | MRNA | Director | Sale | 15.0K | $2.2M |
| Jun 11, 2024 | MRNA | Director | Sale | 202.8K | $30.1M |
| Jun 7, 2024 | MRNA | Director | Sale | 15.0K | $2.3M |
| May 31, 2024 | MRNA | Director | Sale | 20.0K | $2.9M |
| May 24, 2024 | MRNA | Director | Sale | 15.0K | $2.4M |
| May 17, 2024 | MRNA | Director | Sale | 15.0K | $1.9M |
| May 10, 2024 | MRNA | Director | Sale | 15.0K | $1.8M |
| May 3, 2024 | MRNA | Director | Sale | 15.0K | $1.7M |
| Apr 26, 2024 | MRNA | Director | Sale | 15.0K | $1.6M |
| Apr 19, 2024 | MRNA | Director | Sale | 15.0K | $1.6M |
| Apr 12, 2024 | MRNA | Director | Sale | 15.0K | $1.6M |
| Apr 5, 2024 | MRNA | Director | Sale | 15.0K | $1.5M |
| Mar 29, 2024 | MRNA | Director | Sale | 15.0K | $1.6M |
| Mar 22, 2024 | MRNA | Director | Sale | 15.0K | $1.5M |
| Mar 15, 2024 | MRNA | Director | Sale | 15.0K | $1.6M |
Showing the 25 most recent filings of 89. Screen every filing.
Noubar Afeyan insider trading FAQ
Is Noubar Afeyan buying or selling?
Across 89 SEC Form 4 filings, Noubar Afeyan reported 3 open-market purchases totaling $170.0M and 86 sales totaling $1.6B — a net selling position of $1.5B.
Which companies does Noubar Afeyan file Form 4s for?
Noubar Afeyan has reported insider transactions at 3 companies, most often Moderna, Inc. (MRNA), Generate Biomedicines, Inc. (GENB), Seres Therapeutics, Inc. (MCRB).
How far back does Noubar Afeyan's filing history go?
Trabud holds Noubar Afeyan's SEC Form 4 filings from Jun 20, 2019 – May 22, 2026, sourced directly from SEC EDGAR.
Where does Trabud get Noubar Afeyan's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track Noubar Afeyan and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener